See References Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org, for additional references pertaining to this table. An adverse prognosis indicates a ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Despite a constellation of available data points regarding prognosis and impacted organs, ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research, published at the ATS 2025 International ...

Results from a phase 1/2 showed that ATYR1923 was safe and well tolerated. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ATYR1923 for the treatment of sarcoidosis.

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...

Stanford University is launching a Phase IIa trial to test baricitinib with a steroid-sparing medication for adults with active cardiac sarcoidosis. The study will track inflammation changes with ...

ATS 2025, San Francisco – Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ...